share_log
Reuters ·  Apr 29 08:55
AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment